Core Viewpoint - The company, Longshen Rongfa (300534), has obtained a Medical Device Manufacturing License from the Gansu Provincial Drug Administration, allowing its blood dialysis concentrate (dry powder) product to be produced and sold [1] Group 1 - The acquisition of the Medical Device Manufacturing License signifies that the company's blood dialysis concentrate (dry powder) product is now qualified for production and market sales [1] - The blood dialysis concentrate (dry powder) is classified as a medical device used in the treatment of acute and chronic renal failure through blood dialysis, and it has been widely applied in clinical settings [1]

Core Viewpoint - The company has obtained a medical device production license for its blood dialysis concentrate (dry powder) product, enabling production and market sales [1] Group 1 - The license was issued by the Gansu Provincial Drug Administration on February 5, 2026 [1] - The blood dialysis concentrate (dry powder) is used for blood dialysis treatment in acute and chronic renal failure and has been widely applied in clinical settings [1]

Core Viewpoint - The company, Longshen Rongfa, has obtained a Medical Device Manufacturing License from the Gansu Provincial Drug Administration, allowing it to produce and sell its blood dialysis concentrate (powder) products, which are essential for treating acute and chronic renal failure [1] Group 1 - The acquisition of the Medical Device Manufacturing License signifies that the company's blood dialysis concentrate (powder) products are now qualified for production and market sales [1] - Blood dialysis concentrate (powder) is widely used in clinical settings for blood dialysis treatment in patients with acute and chronic renal failure [1] - This license acquisition will facilitate the company's production and operational efforts for the blood dialysis concentrate (powder) products, enhancing its industry layout and fostering new profit growth points [1] Group 2 - The development is expected to improve the company's overall market competitiveness and has positive implications for its future growth [1]

Group 1 - The company, Longshen Rongfa, announced that it obtained a medical device production license from the Gansu Provincial Drug Administration on February 5, 2026 [1] - The production scope of the license includes Class III medical devices specifically for blood purification and peritoneal dialysis equipment [1]

陇神戎发公告，公司于2026年2月5日取得由甘肃省药品监督管理局核发的《医疗器械生产许可证》，许 可证编号为甘药监械生产许20260001号。本次取得《医疗器械生产许可证》标志着公司血液透析浓缩液 （干粉）产品具备生产和上市销售的资质。 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2026-003 甘肃陇神戎发药业股份有限公司 关于取得《医疗器械生产许可证》的公告 统一社会信用代码：91620000720238148G 住所：甘肃省兰州市榆中县定远镇国防路 10 号 法定代表人：康永红 企业负责人：孙波 生产地址：甘肃省兰州市榆中县定远镇国防路 10 号 生产范围：Ⅲ类：10-04-血液净化及腹膜透析器具*** 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）于 2026 年 2 月 5 日 取得由甘肃省药品监督管理局核发的《医疗器械生产许可证》，现将有关情况公 告如下： 一、《医疗器械生产许可证》基本信息 许可证编号：甘药监械生产许 20260001 号 企业名称：甘肃陇神戎发药业股份有限公司 尚无法预测其对公司未来业绩的具体影响，敬请广大投资者谨慎决策，注意投资 风险。 三、备查文件 1.《医疗器械生产许可证》 特此公告。 甘肃陇神戎发药业股份有限公司董事会 2026 年 2 月 5 日 许可期限：自 2026 年 2 月 4 日至 ...

Group 1 - The core viewpoint of the article emphasizes that the newly released "Special Regulations on the Registration Management of Traditional Chinese Medicine" is a significant measure to promote high-quality development in the traditional Chinese medicine industry [2] - The company, as a traditional Chinese medicine manufacturer, strictly adheres to national drug regulatory laws and quality standards in its production and operations [2] - The company actively aligns with the new regulations to continuously strengthen quality control, ensuring that its products meet the latest national standards [2] - The relevant policies are not expected to adversely affect the company's operations [2]

Group 1 - The core point of the article is that Longshen Rongfa (300534) announced the relocation of its subsidiary, Gansu Pharmaceutical Group Sanyuan Pharmaceutical Co., Ltd., which has received a new Drug Business License from the Gansu Provincial Drug Administration due to the change of warehouse address [1] - The new warehouse is located at No. 10, National Defense Road, Dingyuan Town, Yuzhong County, Lanzhou City, and the license is valid until September 18, 2028 [1] - The business scope of the subsidiary includes wholesale of traditional Chinese medicine pieces, Chinese patent medicines, chemical drugs, and biological products [1]

证券代码：300534 证券简称：陇神戎发 公告编号：2026-002 甘肃陇神戎发药业股份有限公司 关于控股子公司取得换发后的《药品经营许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃药业 集团三元医药有限公司（以下简称"三元医药"）因仓库地址变更申请更换《药 品经营许可证》，于近日收到甘肃省药品监督管理局换发后的新证。现将有关情 况公告如下： 统一社会信用代码：91620102MA73LG7052 经营地址：甘肃省兰州市城关区广武门街道秦安路 184 号第 6 层 601-603、 606、608、610 室 法定代表人（负责人）：张帆 主要负责人：刘军 质量负责人：魏萍 经营范围：中药饮片、中成药、化学药（含原料药）、生物制品，上述经营 范围含冷藏药品*** 经营方式：批发（法人） 仓库地址：甘肃省兰州市榆中县定远镇国防路 10 号 有效期至：2028 年 9 月 18 日 一、换发后的《药品经营许可证》基本信息 企业名称：甘肃药业集团三元医药有限公司 许可证编号：甘 AA93 ...

Group 1 - The company is actively seeking partnerships with both domestic and international partners to promote the internationalization of traditional Chinese medicine [2] - The company's products, including Yuanhu Zhitong Droplets and Huangqi Danggui Capsules, have been registered and are being sold in Thailand [2]